



A RESEARCH REVIEW™
CONFERENCE REVIEW

ECTRIMS 2021

Making Education Easy

13–15 Oct 2021

In this review:

- MRI activity vs relapses as markers of disease activity in SPMS
- If and when to stop DMT in relapsing MS
- If and when to stop DMT in progressive MS
- Difficulties in diagnosis of PPMS
- Economic burden of SPMS
- Real-world experience with ocrelizumab in patients with PPMS
- Humoral immune response to SARS-CoV-2 vaccines in patients with MS
- The impact of smoking cessation on MS disease progression
- Vaccinations in patients with MS
- Bexarotene causes age-dependent remyelination in patients with RRMS

Abbreviations used in this review

COVID-19 = coronavirus disease 2019
CSF = cerebrospinal fluid
DMT = disease-modifying therapy
EAN = European Academy of Neurology
ECTRIMS = European Committee of Treatment and Research in MS
EDSS = Expanded Disability Status Scale
MRI = magnetic resonance imaging
MS = multiple sclerosis
PPMS = primary progressive MS
RRMS = relapsing-remitting MS
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
SPMS = secondary progressive MS

Welcome to our review of the 37th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) that was held online recently.

The scientific programme comprised well-known session formats such as Scientific Sessions, Hot Topics and Meet the Experts, as well as live discussions between the international faculty and participants at the end of each session. I have selected and reviewed 10 presentations from ECTRIMS 2021 that I found to be particularly interesting. All abstracts have been published in an online supplement of the [Multiple Sclerosis Journal](#), and more information about the meeting can be found at <https://www.ectrims-congress.eu/2021.html>.

I hope you find this conference review informative and relevant to your practice.

Kind regards

Dr John Mottershead

johnmottershead@researchreview.co.nz

MRI activity versus relapses as markers of disease activity in SPMS: Data from real world and pivotal clinical studies

Speaker: Gavin Giovannoni, UK

Summary: This study analysed data from the Adelphi real-world MS Disease Specific Programme (Adelphi MS DSP) and the phase 3 EXPAND study to evaluate the contribution of MRI activity and relapses in defining disease activity in patients with SPMS. 2554 patients with SPMS from the Adelphi MS DSP were categorised as having active SPMS (n=1889) or non-active SPMS (n=665). Active SPMS was defined on the basis of MRI lesions (59.1%), relapse status (12.6%), and both MRI and relapse (28.3%). Over the past 12 months, active SPMS patients had had a lower mean EDSS score (4.6 vs 5.2), a higher proportion of patients undergoing MRI (87.7% vs 58.7%), and more MRIs per patient (1.24 vs 0.87) than non-active SPMS patients. More non-active SPMS patients than active SPMS patients were without treatment (45.1% vs 23.4%). In EXPAND (n=1645), 52.6% of patients who had no relapse in the 2 years prior to screening and no Gd+T1 lesions were categorised as having non-active SPMS. Of the non-active SPMS patients who were randomised to receive placebo, 52.7% experienced on-study relapse and/or MRI activity.

Comment: This is a great study from a UK group. They have looked to see whether patients with SPMS can be meaningfully split into active and inactive groups and whether the inactive patients stay inactive. SPMS is the progressive form of MS that follows the initial relapsing-remitting phase after a latency of around 10 years in many patients. In this study, patients who had experienced neither new MRI lesions nor recent relapses had a more than 50% chance of reactivating over the next few years, with new MRI activity, relapses or both. MRI activity happened significantly more often than relapses, presumably because some MRI lesions develop in areas that are not clinically eloquent. Pharmac access criteria for initiation of DMT require a relapse in the last 12 months (or 2 in the last 24 months), plus new MRI activity on a scan within the last 2 years. This study suggests that even in patients with established SPMS, it is worth arranging an MRI to look for activity if there has been relapse activity.

Clinical aspects of MS – Diagnosis and differential diagnosis: P001

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Independent commentary by Dr John Mottershead



Dr John Mottershead is a Neurologist at SDHB. He trained at Oxford University as a medical student and after qualification and junior doctor jobs was involved in research into uses of MRI in MS under the supervision of Professor Ian McDonald at Queen Square, London, before completing his neurology training in the South West of England. From 2002 to 2009 he was a neurologist in Manchester, where he gained further experience in general neurology and worked in the busy MS disease-modifying treatment clinic that served Greater Manchester. In 2009 he and his family moved to Dunedin. In 2013 he received an MSc in Clinical Education, with Distinction, from Edinburgh University. He continues to have a clinical interest in MS and other demyelinating disorders.



Disease-modifying treatment – if and when to stop in relapsing MS

Speaker: Ilya Kister, US

Summary: This literature review investigated whether DMTs should be used indefinitely in patients with RRMS, and discussed the pros and cons of therapy discontinuation in patients deemed to be at 'low risk' for disease reactivation. More than 12 recent studies were identified that directly addressed the question of DMT discontinuation; all of these studies were observational and many were retrospective. The available literature does not allow for an evidence-based decision of whether or when it may be safe to stop DMT, but provides a framework for a discussion of the pros and cons of DMT discontinuation. Various demographic, clinical, radiologic, and laboratory variables were identified that may be relevant for assessing the risk of post-discontinuation relapse. However, even in patients at low risk for relapses, it is unknown whether DMT discontinuation may impact progression independently of relapse activity, subclinical disease activity, and brain atrophy. The potential negative impact of DMT discontinuation needs to be weighed against the risk of prolonged immunosuppression/immunomodulation in ageing and more disabled patients, especially in the era of COVID-19. Three ongoing randomised trials of DMT discontinuation are expected to generate higher-level evidence for making this difficult decision.

Comment: More than 50% of the 3000 plus patients with MS in NZ are receiving DMTs. It is unlikely that all of them will benefit from continual treatment for the whole of their lives. But when is it safe to stop? This presentation reviewed the literature. All available studies were retrospective and mostly looked at stopping the older injectable drugs, beta-interferon and glatiramer acetate. The message seems to be that people under 45 years old, those with recent new changes on MRI, and those with recent relapse activity are at greater risk for reactivation on withdrawal of therapy. Given that older people seem to be at higher risk for serious complications from high efficacy immunomodulatory agents, there is likely to be an argument to stop therapy in older people with MS who have had no recent MRI or relapse activity. Prospective studies looking at this issue are already underway, but the outcomes may not be clear cut, given the number of factors in play.

Hot Topic 7: Disease modifying treatment – if and when to stop; 066

Disease-modifying treatment – if and when to stop in progressive MS?

Speaker: Gavin Giovannoni, UK

Summary: Stopping a maintenance anti-inflammatory DMT in more advanced or progressive MS carries the risk of rebound inflammatory activity. Evidence suggests that patients who had highly active disease when they started DMTs tend to 'reactivate' after stopping them. Factors such as immunosenescence, infection, cancer risk, vaccine-responsiveness, and comorbidities (particularly cardiovascular risk) need to be weighed up when deciding whether to continue or stop DMT. One option is a de-risking strategy (switching to safer immunomodulatory therapies) and another is to select an immune reconstitution therapy that is not associated with long-term immunosuppression in this phase of the disease. In addition, combination therapies and additional therapeutic targets may be considered instead of stopping DMTs. Randomised controlled withdrawal studies are needed to generate evidence-based criteria for stopping DMT in patients with progressive MS.

Comment: Recent changes in Pharmac funding criteria mean that many people with MS in NZ may stay on treatment until they progress to the point where they are unable to walk 100m with or without assistance. These changes are welcome, but do mean that some people may potentially stay on therapy into old age, and at relatively high levels of disability. As with the presentation on stopping treatment in relapsing MS reviewed above, many of the answers as to the right way to proceed are still unclear. One possible strategy would be to de-escalate therapy from high efficacy to lower efficacy agents in older people with no recent MRI or relapse activity. Against this, we know that the effectiveness of lower efficacy agents in progressive MS is less convincing than for the high efficacy agent ocrelizumab, although this may be in part because clinical trials used ambulation as the main outcome measure, rather than upper limb, bulbar and cognitive function which may be more sensitive to intervention in later-stage MS.

Hot Topic 7: Disease modifying treatment – if and when to stop; 067

Difficulties in diagnosis of primary progressive multiple sclerosis

Speaker: Katelijin Blok, the Netherlands

Summary: This study identified common difficulties in diagnosing PPMS in a real-world setting. The records of 322 patients with a diagnosis of PPMS in 2 MS centres were reviewed, and the diagnosis of PPMS was reassessed using a predefined set of criteria. The original diagnosis met the predefined criteria for 48% of cases. For the remaining patients, at least one of the following problems was observed: incomplete diagnostic work-up; reported episodes suggestive of remyelination in the previous medical history; failure to exclude other possible diagnoses; not meeting 2017 McDonald criteria despite full diagnostic work-up; and other concomitant diagnoses that blurred the MS disease course.

Comment: PPMS amounts to around 15% of cases. It presents at an older age – often 40s or 50s, and the male to female ratio is equal. As this study shows, diagnosis is often difficult. One reason for this is the absence of characteristic relapses – in relapsing onset MS an episode of, say, optic neuritis is a big diagnostic clue. Another problem is that, as we get older, white matter lesions on MRI due to small vessel ischaemia become more commonplace, so MRI is a less reliable diagnostic tool. Hereditary spastic paraparesis, mechanical cervical myelopathy, motor neurone disease and cerebrovascular disease may all sometimes present in ways that may cause confusion with PPMS. I would be more likely to arrange CSF studies looking for oligoclonal bands when investigating older people with a non-relapsing course, especially if there were no enhancing lesions seen on MRI. Positive oligoclonal bands and/or enhancing MRI lesions provide reasonable support for a diagnosis of MS.

Clinical aspects of MS – Diagnosis and differential diagnosis; P020

Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: The DISCOVER study

Speaker: Celia Oreja-Guevara, Spain

Summary: The DISCOVER study investigated the health-related and non-health-related costs of SPMS. 297 patients who were treated and monitored according to routine clinical practice at 34 sites in Spain were included; the primary outcome was the estimated total annual cost per patient (including health and non-health-related direct costs and indirect costs). Mean age was 54.6 years, and patients had a median EDSS of 2.0, 5.3 and 6.0 at MS diagnosis, SPMS diagnosis and study visit, respectively. 19.9% of patients had active SPMS. The majority (89.6%) of patients were unemployed, and most (71.7%) of these patients had permanent disability. Patients with higher EDSS had a lower health-related quality of life as measured by EuroQol 5 Dimension 5 Level utility index. Total annual cost per patient was 41,448.58€, which comprised health-related resources (11,310.86€), non-health-related resources (8,775.34€), and indirect costs (21,362.37€). Costs ranged from 34,880.43€ for patients with an EDSS score of 3–3.5 to 46,218.88€ for patients with an EDSS score of 6.5.

Comment: SPMS follows on from the relapsing-remitting phase and is often only diagnosed retrospectively, after walking difficulties, bladder problems, ataxia and cognitive issues have built up gradually. This study looked at patients with established SPMS – on average these were people who would require assistance to walk more than very short distances. The findings are that there are large health-related, non-health-related and indirect societal costs. The aim of early intervention with DMTs is to reduce or delay secondary progression. Although the costs of modern treatments are high, this and other studies show that the potential financial benefits of successful treatment are very considerable. Intervening once SPMS is already established may possibly slow disability trajectories, but is unfortunately not likely to be as effective in terms of health or economic outcomes.

Clinical aspects of MS – Economic burden; P274

SUBSCRIBE FREE
www.researchreview.co.nz





TYSABRI
(natalizumab)

A LOT CAN CHANGE in 6 months



TIME MATTERS^{#5}

[#]Time is critical in preventing brain damage caused by RRMS.⁵

TYSABRI works fast¹⁻³ to start reducing further brain damage in RRMS,⁴ with

*>80% mean saturation of $\alpha 4$ integrin receptors at 4 hours^{†1}

*>85% reduction in new Gd+ lesions within 1 month^{‡2}

*87% reduction in annualised relapse rate within 3 months.^{§¶3}

Why wait any longer?

[†]Laboratory data do not necessarily predict clinical effects. [‡] $p < 0.01$ vs placebo. [§] $p < 0.0001$ for reduction from baseline. [¶]Findings from *post hoc* and open-label observational studies should be interpreted with caution.

BEFORE PRESCRIBING, PLEASE REVIEW APPROVED DATA SHEET AVAILABLE AT <https://www.medsafe.govt.nz/profs/Datasheet/t/Tysabriinf.pdf>


WARNING: TYSABRI is associated with an increased risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that may lead to death or severe disability. Healthcare professionals should closely monitor patients on TYSABRI for any new or worsening signs or symptoms that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first signs or symptoms suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain, neurological assessment and cerebrospinal fluid analysis for JC viral DNA are recommended (see section 4.3 CONTRAINDICATIONS and section 4.4 PRECAUTIONS, Progressive Multifocal Leukoencephalopathy).

INDICATIONS: Monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (MS) to delay the progression of physical disability and to reduce the frequency of relapse. **DOSE:** 300 mg by IV infusion every four weeks. Infuse over approx. 1 hour with 1 hour observation. **CONTRAINDICATIONS:** Known hypersensitivity to natalizumab, its excipients, or murine derived proteins. History of, or current, progressive multifocal leukoencephalopathy (PML). Patients with increased risk for opportunistic infections, including those immunocompromised due to current or recent immunosuppressive therapies or systemic medical conditions. TYSABRI should not be administered in combination with immunomodulatory agents. **PRECAUTIONS:** TYSABRI has been associated with PML, other opportunistic infections (including herpes infections with CNS manifestations and acute retinal necrosis), hypersensitivity reactions and liver injury. If any of these adverse events occur discontinue therapy. Patients should be regularly monitored, with continued vigilance for PML for 6 months following cessation of TYSABRI. Early diagnosis, clinical and MRI monitoring and stopping therapy are important in managing PML. Annual MRI recommended; consider more frequent MRIs in patients at higher risk of PML. The following risk factors are associated with an increased risk of PML: (i) presence of anti-JCV antibodies, (ii) treatment duration especially beyond 2 years in anti-JCV antibody positive patients, (iii) immunosuppressant use prior to receiving TYSABRI. Patients who have all three risk factors have a significantly higher risk of PML and the benefit-risk of continuing treatment with TYSABRI should be carefully considered. In patients not previously treated with immunosuppressants, index value further stratifies risk of developing PML. Anti-JCV antibody testing should be performed prior to initiating TYSABRI therapy or in patients already receiving TYSABRI in whom antibody status is unknown. Anti-JCV antibody assays should not be used to diagnose PML and should not be performed for at least two weeks following plasma exchange or 6 months following use of IVIG. If symptoms suggestive of PML occur, immediate dose suspension is required until PML is excluded. If initial investigations prove negative, but clinical suspicion for PML still remains, TYSABRI should not be restarted and repeat investigations should be undertaken. If a patient develops PML, permanently discontinue TYSABRI to enable restoration of immune function. In patients that develop PML, monitor for development of Immune Reconstitution Inflammatory Syndrome (IRIS) after removal of TYSABRI (e.g. via plasma exchange (PLEX)). IRIS presents as a worsening in neurological status that may be rapid, which can lead to serious neurological complications and may be fatal. No difference was observed on 2-year survival after PML diagnosis between patients who received PLEX and those who did not. Symptoms of JCV granule cell neuropathy are similar to PML. Careful consideration is required before commencing other therapies following discontinuation of TYSABRI. Use in Pregnancy Category C. TYSABRI has been detected in human milk. **ADVERSE EFFECTS:** Very Common: nasopharyngitis, dizziness, nausea. Common: urinary tract infection, urticaria, headache, vomiting, arthralgia, rigors, pyrexia, fatigue. Serious: Opportunistic infections, hypersensitivity reactions, liver injury, uncommon thrombocytopenia and immune thrombocytopenic purpura, rare haemolytic anaemia. TYSABRI is a Prescription Medicine. TYSABRI concentrated injection solution contains 300mg/15mL natalizumab in a sterile, single use vial free of preservatives (pack of 1 vial). TYSABRI is a funded medicine – a prescription charge and Special Authority criteria will apply. **NAME AND ADDRESS OF SPONSOR:** Biogen NZ Biopharma Limited, 188 Quay Street, Auckland. **REVISION DATE:** January 2021.

References: 1. Plavina T *et al.* *J Clin Pharmacol* 2016; 56(10): 1254-1262. 2. Rudick R *et al.* *JAMA Neurology* 2013; 70(2): 172-182. 3. Kappos L *et al.* *J Neurol* 2013; 260: 1388-1395. 4. TYSABRI Approved Data Sheet, November 2020. 5. Giovannoni G *et al.* *Brain Health: Time Matters in Multiple Sclerosis*. Available online at www.msbrainhealth.org Accessed November 2020. Biogen® and TYSABRI® are registered trademarks of Biogen MA Inc. ©2021. Biogen-92751. TAPS BG1175. BIOG0871/EMBC. Date of preparation: May 2021.



For more information, please go to www.medsafe.govt.nz



Real world experience with ocrelizumab in patients with primary progressive multiple sclerosis: Insights from the German NeuroTransData Registry

Speaker: Stefan Braune, Germany

Summary: This report described the real-world experience with ocrelizumab in patients with PPMS. 460 patients registered with the German NeuroTransData registry (a network of 66 neurology outpatient services across Germany) were included; 82 of whom were treated with ocrelizumab. Ocrelizumab recipients were younger (mean age 51.5 vs 62.3 years), had a shorter time from first PPMS symptoms (mean 8.69 vs 18.74 years), and had similar EDSS scores (mean 4.44 vs 4.99) compared to the overall PPMS cohort. The mean ocrelizumab treatment duration was 1.5 years. Persistence was 98.7% at 12 months and 94.8% at 24 months, and administration of infusions followed the recommended schedule. During the observation period, no significant change in EDSS score was noted.

Comment: PPMS has for a long time been resistant to treatment – the same drugs that have shown efficacy in relapsing MS have failed when tried in PPMS. This changed a few years ago when ocrelizumab, a monoclonal antibody similar to rituximab, which targets B-cells, achieved positive outcomes in a clinical trial. The benefits in slowing disability were smaller than those seen with the same drug in relapsing MS, but were nevertheless a welcome piece of good news. This study looked at the German experience with ocrelizumab in this patient population. The results are encouraging – there was high persistence on treatment and short-term stability of disability levels. Pharmac is currently looking into funding ocrelizumab for PPMS in NZ. Ocrelizumab has not been through trials in SPMS, but it would be surprising if it were not at least as effective there as it is in PPMS.

Clinical aspects of MS – Progressive MS; P117

Comparing humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and healthy controls

Speaker: Gabriel Bsteh, Austria

Summary: This multicentre trial in Austria evaluated humoral immune response to SARS-CoV-2 vaccines in 467 patients with MS compared with 124 healthy individuals. Preliminary analyses show that 89.9% of MS patients and 97.6% of healthy controls developed protective levels of anti-SARS-CoV-2 immunoglobulin G antibodies. Positivity rate was significantly lower in patients on immunosuppressive DMTs (63.8%) than in patients not on DMTs (91.7%) or on immunomodulatory DMTs (92.9%). Seroconversion was lowest in patients taking anti CD-20 monoclonal antibodies (55.2%) or sphingosine-1 receptor modulators (75%).

Comment: COVID-19 vaccination is very much in the news. This study adds to previous data, especially from Israel, which show that vaccination seems to be safe in MS, with no signal to suggest that relapses are triggered. Immunity levels following vaccination are similar to those seen in healthy controls, apart from for those patients taking sphingosine-1-phosphate modulators like fingolimod, or anti CD-20 monoclonal antibodies like ocrelizumab, who have lower antibody responses. When choosing a treatment, potential effects on vaccine-related protective immunity are now a significant consideration, and often the approach may be to delay initiation until a patient has been doubly vaccinated, if other factors suggest that ocrelizumab or fingolimod is the best agent to use. The prospect of booster vaccinations obviously complicates things further, and I now talk through these issues before finalising treatment choice with the individual. Things are simpler with the other funded drugs, which seem to have little or no effect on vaccine response.

Scientific Session 18: Late Breaking News; 186

The impact of smoking cessation on multiple sclerosis disease progression

Speaker: Jeff Rodgers, UK

Summary: This study investigated the impact of smoking cessation on disease progression in patients with MS. 7983 adults with confirmed MS who were registered on the UK MS Register were included. 4130 (51.7%) participants had ever smoked, of whom 1315 (16.5%) were still smokers and 2815 (68.2%) were former smokers. For all patient-reported outcomes, adults who were still smokers at the time of completing their first questionnaire had higher disability than those who had never smoked. There was no improvement in patient-reported outcomes with increasing time since quitting in former smokers. A prospective parallel group analysis (n=922) demonstrated that normalised MS Physical Impact Scale, normalised MS Walking Scale, and Hospital Anxiety and Depression Scale (HADS) depression worsened significantly over a period of 4 years, whereas HADS-anxiety remained stable. Post-hoc analysis showed that being a still smoker was associated with a worse score than never smokers for the MS Physical Impact Scale and MS Walking Scale, whereas former smokers were no different from never smokers.

Comment: Smoking has been found to be a risk factor for development of MS in many studies, and may also be associated with a less favourable clinical course. This large UK registry study presented both retrospective and prospective data. The most interesting results were that, despite starting at the same patient-reported disability level, current smokers progressed more rapidly than former smokers and experienced higher levels of mood disturbance as well as increased disability. It seems likely that this is a causal effect, unless there is something about the biological situation of a person who is more likely to progress that makes it harder for them to give up smoking. The practical take-home message is that people with MS should be encouraged to stop smoking, not just for the usual reasons, but also because their MS prognosis may be better if they are successful. Lifestyle advice is increasingly a part of MS management, with exercise and dietary factors also worthy of attention.

Scientific Session 7: Epidemiology in MS – what we know, don't know and why; 065



At all stages of your medical career, the NZMA is your voice, advocating on the issues that affect you, your colleagues and the health of all New Zealanders. A strong membership means we can do more.

Join us today.
www.nzma.org.nz
or scan the code above



RACP MyCPD Program participants can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.

Please [CLICK HERE](#) to download CPD Information

NZ health professionals can subscribe to or download previous editions of Research Review publications at www.researchreview.co.nz



Recommended standards for vaccinations in MS patients

Speaker: Susana Otero-Romero, Spain

Summary: This joint statement on behalf of theECTRIMS-EAN presented evidence-based guidelines for vaccination in patients with MS. Current evidence indicates that vaccines are not associated with an increased risk of relapse or disability accrual in MS patients with or without DMTs, and the benefits of immunisation greatly outweigh any potential risks.


Comment: The COVID-19 pandemic has thrown the whole area of vaccination into greater focus. As a result, clinicians are thinking more about vaccination status in general when dealing with people who may need to start immunomodulatory treatments. In this work, a European committee has drafted guidelines for vaccination in MS patients. They reviewed available evidence and then used a modified Delphi process to achieve at least 80% consensus on recommendations. Broadly speaking, they suggest that immunisation status should be ascertained early on in people with MS, and where there are gaps, vaccination should be offered against measles-mumps-rubella, diphtheria-pertussis- tetanus, varicella zoster virus, and in some patients hepatitis B, human papillomavirus, herpes zoster, pneumococcus and influenza. Inactivated vaccines may be given safely to patients on immunosuppressive drugs, but efficacy may be reduced. Live attenuated vaccines should be given prior to starting immunosuppressive therapy, if indicated. The benefit of dealing with immunity gaps soon after diagnosis is that there will not need to be any delay in starting immunosuppressive therapy later on.

ECTRIMS-EAN Session; 181



Research Review
New Zealand is now
on LinkedIn

FOLLOW US TO KEEP UP TO DATE



An RXR agonist causes age-dependent remyelination in people with relapsing remitting MS

Speaker: Christopher E McMurrin, UK

Summary: The phase 2a CCMR One trial showed that the retinoid-X receptor agonist bexarotene improved neurophysiological and radiological markers of remyelination in RRMS patients aged 25–50 years. This post-hoc analysis of the results investigated whether the remyelination associated with bexarotene varies with patient age. For eyes with chronic optic neuropathy, bexarotene shortened full-field visual evoked potential (VEP) P100 latency maximally in younger patients. P100 improvement in the treatment group diminished by 0.45 ms/year, such that bexarotene had no significant benefit over placebo in patients aged ≥42 years. There was a similar age-related decline in deep grey matter remyelination, with no significant treatment effect in patients aged ≥42 years. In the other 2 brain regions sensitive to bexarotene (cortical grey matter and brainstem), remyelination did not significantly decline with age.

Comment: Remyelination occurs naturally in people with MS, resulting in plaques changing from having a bright white appearance on T2-weighted MRI to become grey “shadow plaques”. Unfortunately, a lot of demyelinated areas fail to remyelinate. Treatments that promote successful remyelination are being actively studied. This paper looked at a trial of a retinoid-X receptor agonist, bexarotene. The small clinical trial showed promising signals for efficacy, as assessed by improvements in VEPs and MRI measures of myelination. Unfortunately, toxicity issues mean that this drug will not go forward to phase 3 trials. The beneficial effects seemed to be restricted to people under the age of 42, mirroring results in experimental rats, where remyelination is more successful in younger animals, partly because of the biochemical environment, and partly because the oligodendrocytes in older animals become less responsive to stimulation. We must hope that other drugs in this class will prove to be safe and effective, preferably for people of all ages.

Free Communication 4: Treatment trials – Neuroprotection and remyelination; 148

SUBSCRIBE AT NO COST TO ANY RESEARCH REVIEW

NZ health professionals can subscribe to or download previous editions of Research Review publications at www.researchreview.co.nz

ABOUT RESEARCH REVIEW

Research Review is an independent medical publishing organisation producing electronic publications in a wide variety of specialist areas. Research Review publications are intended for New Zealand medical professionals.

ABOUT CONFERENCE REVIEWS

Conference Reviews are prepared with independent commentary from relevant specialists. To become a reviewer or to commission a conference review contact admin@researchreview.co.nz

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).